Augmentin (+Clavulanic)

Selected form

Method of action: Antibacterial Broad Spectrum (Bactericidal), Bactericidal, Bactericidal Broad Spectrum

Treatment option: Bronchopneumonia, Pneumonia, Pharyngitis

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Augmentin (+Clavulanic)

Quick Facts

Property	Description
Active Ingredients	Amoxicillin and Clavulanic Acid
Form	Tablets, Oral Suspension, Powder for Injection
Pharmacological Class	β-Lactam Antibiotic and β-Lactamase Inhibitor Combination
General Use	Treating Systemic Bacterial Infections
Origin	Semisynthetic

Defining Amoxicillin/Clavulanic Acid: A Fixed-Dose Antibacterial Combination

The medicine known by its International Nonproprietary Name (INN) as Amoxicillin and Clavulanic Acid (Co-amoxiclav) is structurally classified as a semisynthetic β-lactam antibiotic. This places it in the broader category of penicillin derivatives, functioning as a specialized agent against susceptible bacterial infections. As a fixed-dose combination, it utilizes two distinct active components. This dual-component product is recognized for its role in treating infections, serving to stop the growth of bacteria.

The combination status is what sets this product apart from single-agent antibiotics. This formulation is classified as a potentiated antibiotic, designed to restore the effectiveness of the primary component, Amoxicillin, against resistance mechanisms that some bacteria have developed. This capability provides an enhanced scope over Amoxicillin monotherapy.

What is Amoxicillin/Clavulanic Acid Made Of and How Does it Work Generally?

The formula relies on the synergistic effect between the antibiotic component, Amoxicillin, and the protective component, Clavulanic Acid (supplied as Potassium Clavulanate). Amoxicillin provides the bactericidal action by targeting the integrity of the bacterial cell wall, while the secondary component acts as a β-Lactamase Inhibitor, binding to the enzymes bacteria use to neutralize Amoxicillin. The β-lactamase inhibitor expands the efficacy of the antibiotic.

This combined action ensures the medicine can effectively function as a broad-spectrum antibacterial agent for the clearance of many common types of resistant microorganisms. A typical, neutral use scenario involves addressing infections where bacterial resistance to non-potentiated penicillins is a known clinical concern.

Available Presentations: Tablets, Suspension, and Injection Forms

The medicine is manufactured in multiple dosage form(s) to address the diverse needs of the target audience, including both adult and pediatric patients. These presentations include solid oral forms (Tablets, Chewable Tablets), a liquid form (Oral Suspension), and a sterile Powder for Injection. These forms facilitate the principal routes of administration—Oral or Intravenous—ensuring therapeutic versatility for managing systemic infections across various clinical settings.

Regulatory References

What side effects are possible with Augmentin (+Clavulanic)?

Possible Side Effects and Safety Information

The most frequently reported adverse reactions associated with Augmentin (amoxicillin and clavulanate) from clinical trials affect the gastrointestinal system and skin. These commonly include diarrhea (incidence higher with extended-release formulations), nausea, vomiting, and skin rashes or urticaria.

Serious and Clinically Significant Adverse Reactions

Serious risks, though rare, are formally documented and warrant caution. These include:

Hypersensitivity Reactions: Serious and occasionally fatal reactions (including anaphylaxis) have been reported, necessitating immediate discontinuation upon occurrence.
Severe Cutaneous Adverse Reactions (SCARs): This category includes Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).
Hepatotoxicity: Liver dysfunction, including cholestatic jaundice and hepatitis, has been reported. Events are usually reversible but have been fatal in extremely rare cases, primarily in patients with serious underlying diseases.
Clostridioides difficile-Associated Diarrhea (CDAD): This intestinal infection can range from mild diarrhea to fatal colitis.
Drug-Induced Enterocolitis Syndrome (DIES): Reported primarily in the pediatric population.

Contraindications and Safety Restrictions

Augmentin is contraindicated in patients with a history of a serious hypersensitivity reaction to any penicillin or other beta-lactam agent, or a history of cholestatic jaundice or hepatic dysfunction associated with previous Augmentin use. Use should generally be avoided in patients with infectious mononucleosis due to the high risk of developing a skin rash.

Special consideration is required for patients with hepatic impairment, where liver function tests should be monitored, and those with severe renal impairment, where certain high-dose formulations are contraindicated. The potential for superinfections due to the overgrowth of non-susceptible organisms, such as Candida and C. difficile, should be considered during therapy.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

Overdose with Amoxicillin and Clavulanic Acid is officially documented to present with several clinical manifestations, primarily affecting the gastrointestinal tract, including diarrhea, vomiting, and stomach pain. Central nervous system effects such as drowsiness or sleepiness are also reported in regulatory documentation.

Documented Severe Outcomes

Regulatory information specifies that high exposure can lead to severe complications primarily involving the renal and neurological systems. Overdose may result in specific signs of renal distress, such as decreased urination and the formation of amoxicillin crystalluria, which carries the potential for acute renal injury. Additionally, the occurrence of convulsions (seizures) is a documented severe manifestation, particularly noted in individuals with impaired renal function due to reduced drug clearance.

Mandated Emergency Action

Official labeling mandates that immediate medical attention must be sought upon suspected overexposure. Emergency services must be contacted immediately if the individual exhibits life-threatening signs, including collapse, a seizure, trouble breathing, or the inability to be awakened. Management is strictly symptomatic and supportive, often requiring interventions focused on maintaining high fluid and urinary output to mitigate renal risks.

Therapeutic Uses of Augmentin (+Clavulanic)

What Amoxicillin/Clavulanic Acid Treats: Main Uses and Benefits

The combination of Amoxicillin and Clavulanic Acid is commonly used across conditions presenting with systemic or localized discomfort. This medication is generally applied in contexts where short-term symptomatic assistance is needed to address bacterial infections, and is considered relevant across therapeutic domains recognized by major health authorities.

This antibiotic combination is applied for managing conditions where symptoms create noticeable physiological strain, including acute bacterial sinusitis, acute otitis media, various skin and skin structure infections, and lower respiratory tract infections. It is also a supportive measure in complex scenarios like infections related to animal bites and surgical prophylaxis. The medicine contributes to easing the overall symptom load during periods of heightened symptoms. It is relevant for managing symptoms in infections where bacterial resistance is a clinical concern.

“This medicine is commonly used when symptoms cluster into patterns requiring supportive management, assisting with maintaining functional stability during difficult episodes.”

Managing Symptoms in Acute Respiratory and ENT Infections

This medicine is applied across domains where additional symptomatic support is needed, involving infections of the ears, lungs, and sinuses. It helps address symptoms that interfere with daily functioning, such as the discomfort and systemic symptoms associated with acute otitis media, sinusitis, and certain lower respiratory tract infections. It contributes to easing the overall symptom load during these episodes.

Quick Fact	Description
Therapeutic Scope	Relevant for conditions characterized by periods of heightened symptoms (acute otitis media, bacterial sinusitis, lower respiratory infections).
Symptom Support	May assist with managing pronounced symptoms related to bacterial infection, such as earache, sinus pressure, fever, and localized inflammation, contributing to improved comfort during periods of heightened symptoms.

Regulatory References

NIH DailyMed Official Prescribing Information

Eligibility and Restrictions for Use

Eligibility to Use Amoxicillin/Clavulanic Acid

The eligibility to use Amoxicillin/Clavulanic Acid (Co-amoxiclav) is formally defined by official regulatory documentation, focusing on patient history, age, and organ function. The medicine is generally permitted for adults and pediatric patients over three months, provided no contraindications are present.

Populations Absolutely Prohibited (Contraindicated)

Use is contraindicated in patients with a history of serious hypersensitivity reaction to penicillins or other beta-lactam antibacterials. It is also prohibited for individuals who have experienced cholestatic jaundice or hepatic dysfunction previously associated with this specific drug combination. Furthermore, certain extended-release formulations are contraindicated in patients with severe renal impairment (creatinine clearance < 30 mL/min).

Populations with Restricted or Conditional Use

Use is generally not recommended for patients with suspected or confirmed infectious mononucleosis. Patients with existing hepatic impairment require cautious use and function monitoring. For renal impairment overall, dosage adjustments are necessary. Use during pregnancy is advised only if clearly needed, and specific pediatric formulations require modified use for infants under 12 weeks due to immature organ function.

What should I know about interactions with other medicines?

The official regulatory profile for Amoxicillin/Clavulanic Acid outlines specific interactions with other medicines and products that modify systemic exposure and pharmacodynamic outcomes, as documented in government labeling.

Documented Drug-Drug Interactions

Interacting Substance	Official Regulatory Outcome
Probenecid	Inhibits the renal tubular secretion of Amoxicillin, leading to increased and prolonged plasma concentrations of Amoxicillin. This is a transporter-mediated pharmacokinetic modification.
Oral Anticoagulants (e.g., Warfarin)	Associated with an increase in the prolongation of prothrombin time (INR) and a heightened risk of bleeding events.
Allopurinol	Concomitant use increases the documented risk of rash.
Oral Contraceptives	Co-administration may lead to reduced efficacy of the contraceptive agent.

Food, Timing, and Population Constraints

Interaction rules related to administration timing require the medicine to be taken at the start of a meal. This procedural constraint enhances the absorption of the Clavulanate Potassium component. Conversely, a high-fat meal may officially decrease Clavulanate absorption for extended-release formulations. Specific population-related constraints exist for patients with organ dysfunction. Increased exposure to Amoxicillin is expected in cases of Renal Impairment due to slower clearance. The medicine is contraindicated in patients with a prior history of drug-associated cholestatic jaundice or hepatic dysfunction.

Mechanism of Action

Augmentin is a co-formulation of amoxicillin and clavulanic acid, each with distinct but cooperative biological targets. Amoxicillin is a beta-lactam antibiotic that targets essential bacterial enzymes located on the inner side of the bacterial cell wall, collectively termed penicillin-binding proteins (PBPs), which are DD-transpeptidases.

Amoxicillin acts as a substrate inhibitor, forming a covalent bond with the active site of the PBPs. This interaction irreversibly inhibits the transpeptidation step necessary for peptidoglycan synthesis, the molecular pathway responsible for the structural integrity and cross-linking of the bacterial cell wall. This inhibition blocks the construction of the protective layer, leading to loss of cellular turgor and subsequent osmotic lysis of the bacteria as a system-level physiological consequence.

Clavulanic acid is a beta-lactamase inhibitor that primarily targets the bacterial enzymes known as beta-lactamases (penicillinases). It acts as a suicide inhibitor, binding irreversibly to the active site of the beta-lactamase enzymes. This molecular interaction sequesters and deactivates the beta-lactamases, preventing their enzymatic hydrolysis of the beta-lactam ring on amoxicillin. This downstream cascade ensures amoxicillin's structural integrity, allowing it to maintain its inhibitory activity against PBPs.

Dosage and Administration Information

How Amoxicillin/Clavulanic Acid (Augmentin) is Used: Official Administration Guidelines

Administration of Amoxicillin and Clavulanic Acid is determined by its formulation, with standardized routes including Oral (tablets, suspensions) and Intravenous (IV) (injection/infusion powder). The precise dosing schedule depends on the severity of the infection and is standardized based on the amoxicillin component. For adults, standard immediate-release regimens are typically administered every 12 hours or every 8 hours, while the extended-release form is administered every 12 hours.

Timing and Preparation

Standard instructions indicate that oral forms should be taken at the start of a meal. This practice is intended to enhance the absorption of the clavulanate component and limit gastrointestinal issues. Oral suspensions require reconstitution with water upon dispensing, and the resulting liquid must be shaken before each use. Intravenous powder must be reconstituted and diluted prior to infusion.

Dosing Constraints and Duration

Therapy is defined as a short course, and treatment generally should not be extended beyond 14 days without reassessment. Dosage requires modification for patients with reduced kidney function (Creatinine Clearance le 30 mL/min); for these individuals, high-dose forms like the 875 mg tablet or Extended-Release formulations are not recommended. Furthermore, certain tablets, such as the Extended-Release forms, must be swallowed whole and cannot be crushed or chewed.

Administration Constraint	Labeled Instruction
Intake Timing	Must be taken at the start of a meal.
Frequency Pattern	Twice Daily or Three Times Daily dosing.
Renal Adjustment	Mandatory dose modification for CrCl le 30 mL/min.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Amoxicillin and Clavulanic Acid

Evidence for Respiratory and ENT Infections

The research base for this combination medicine’s evaluation in respiratory, ear, and sinus infections is largely composed of Randomized Controlled Trials (RCTs) and systematic reviews, which provide a structured type of evidence. These studies were conducted during periods of increased symptom activity in both adult and pediatric populations.

For acute bacterial sinusitis, studies explored how outcomes related to physical discomfort and symptoms change over time. Some trials report measurements of Study endpoints related to Clinical Status when compared against other treatments. Findings can vary, and research suggests that the observed outcomes in the control (placebo) groups demonstrated spontaneous symptom resolution in a large proportion of participants.

For acute otitis media, the evidence describes the observation of Study endpoints related to Clinical Status and Symptom Resolution in young children. Findings indicate that the medicine was associated with patterns of symptom change and microbiological study endpoints in the observed populations.

Evidence for Skin, Soft Tissue, and Other Systemic Infections

The research supporting the evaluation of this medicine in skin and soft tissue infections is based on a mix of comparative trials and observational data. Studies were evaluated in research contexts involving infections where bacterial resistance is a clinical concern. Researchers monitored outcomes related to physical discomfort and Study endpoints focused on physical signs over short-term periods, typically 7 to 14 days. This evidence contributes to understanding symptom patterns across a broad grouping of localized infections in the general adult and pediatric populations.

For urinary tract infections (UTIs), studies observed responses related to both the resolution of symptoms and Microbiological study endpoints (clearance of microorganisms from cultures). For infections resulting from animal or human bites, evidence is primarily derived from clinical case series and syntheses used to create official treatment guidelines.

Analysis of Research in Pediatric and Vulnerable Populations

The research base includes a large volume of studies focused on Pediatric patients, as much of the core research for conditions like acute otitis media has focused on infants and young children. Research describes the use of formulations tailored for children. Data for the youngest infants (under three months of age) remain insufficient or limited. For Older Adults, studies have been conducted, and findings generally describe patterns of response in the observed populations. Research documents describe that physiological factors in older adults were accounted for during the study protocols. Limited information is available regarding the observed outcomes in pregnant or breastfeeding populations.

Areas of Uncertainty and Research Limitations

A recognized research limitation across many indications is that the existing data for the medicine requires ongoing evaluation against the emergence of resistant bacteria. Research is ongoing to address whether studies continue to observe similar patterns of response against certain emerging, highly resistant strains.

Comparative evidence is limited in some areas, meaning direct, head-to-head trials against all relevant comparison treatments may not be available for every approved use. Sample sizes were modest in some older trials. Finally, the results apply only to the populations studied, meaning findings reflect group patterns but research does not determine whether an individual with unique health factors will respond similarly.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Augmentin (+Clavulanic) (FAQ)

Q: Why do some people experience yeast infections while on Augmentin?

Official prescribing information notes the potential for microbial overgrowth during therapy. The drug’s safety profile mentions the possibility of superinfections with non-susceptible organisms, such as Candida species, which is the organism commonly associated with yeast infections.

Q: Is there a generic version of Augmentin available?

The medicine is known by its International Nonproprietary Name (INN), which is Amoxicillin and Clavulanic Acid. This combination medicine is described in official sources as being available generically from a number of different manufacturers.

Q: Can Augmentin cause dizziness or lightheadedness?

The official drug labeling indicates that adverse reactions have been reported in postmarketing experience concerning the central nervous system. This system includes effects that may manifest as dizziness, lightheadedness, or other related neurological symptoms.

Q: Can Augmentin change the color of my urine?

Official information notes that high concentrations of the amoxicillin component in the urine can affect the results of certain laboratory tests. Specifically, amoxicillin may result in false-positive reactions when testing for the presence of glucose in urine using non-enzymatic methods. There is no explicit mention in the official label that the medicine changes the color of urine itself.

Q: Can Augmentin cause insomnia or affect sleep?

The official drug labeling notes that adverse reactions involving the central nervous system have been reported based on postmarketing experience. This category includes a range of potential neurological effects that could influence sleep patterns.

Q: How is the dosage determined for Augmentin in children?

For pediatric patients aged three months and older who weigh less than 40 kg, regulatory documents describe that the dosage is determined by the child's body weight (expressed in milligrams per kilogram per day). The final dosage pattern is also adjusted based on the severity and location of the infection being treated.

Q: What research evidence exists about using Augmentin for pneumonia?

The medicine is officially indicated for the treatment of various bacterial infections, including those classified as Lower Respiratory Tract Infections. This specifically covers Community-Acquired Pneumonia (CAP) when caused by susceptible organisms, and the research base supports its use for this indication.

Q: Can Augmentin affect the results of certain medical tests?

Official documents state that the medicine is known to potentially interfere with specific laboratory tests. High urine concentrations of the amoxicillin component can interfere with certain non-enzymatic tests used to check for glucose in the urine, potentially resulting in false-positive results.

Q: Are headaches a potential side effect of Augmentin?

Official safety information describes that the central nervous system is one of the organ systems where adverse reactions have been reported in postmarketing experience. This category encompasses a variety of potential neurological effects, which can include headaches.

Q: Is it true that Augmentin can cause confusion or strange thoughts?

Adverse reactions affecting the central nervous system have been reported in postmarketing experience, according to regulatory documents. This system controls mental processes, meaning effects such as confusion are noted within the drug's safety profile.

Q: Is it necessary to finish the entire course of Augmentin even if I feel better?

Official usage information emphasizes the importance of using the drug only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. This strict approach is intended to help reduce the development of drug-resistant bacteria and maintain the effectiveness of this and other antibacterial agents.

How should Augmentin (+Clavulanic) be stored and disposed of?

How to Store and Dispose of Amoxicillin and Clavulanate Potassium

The official storage requirements for this medication are strictly dependent on the formulation, as mandated by regulatory documents. All forms must be kept out of the sight and reach of children.

Formulation	Required Storage Condition	Stability/Handling Rule
Tablets / Dry Powder	Store in the original container at or below 25 C (77 F) to protect from moisture.	Use tablets within 30 days of opening the foil pouch.
Reconstituted Suspension	Must be stored under refrigeration (2 C to 8 C). The suspension must not be frozen.	Must be discarded after 7 or 10 days, depending on the specific label, regardless of volume remaining.